Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028

Reuters01-13
Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028

ACADIA Pharmaceuticals Inc. projects strong commercial growth, forecasting approximately $1.7 billion in global net sales by 2028. The company expects NUPLAZID to contribute around $1 billion and DAYBUE approximately $700 million to this total. This outlook reflects significant momentum in both products and underscores the company's expectations for sustained business performance growth over the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113614282) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment